• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Business & Finance

2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income todayheadline

March 26, 2025
in Business & Finance
Reading Time: 3 mins read
A A
0
ABT Revenue (Annual) Chart
4
SHARES
9
VIEWS
Share on FacebookShare on Twitter


Equities haven’t performed well this year due to a combination of factors. Macroeconomic tensions are at the top of that list. Still, some companies are doing just fine amid the volatility, including AbbVie (ABBV -3.73%) and Abbott Laboratories (ABT -1.35%). These two healthcare leaders may or may not continue beating the market in the next few weeks — it’s challenging to predict the direction of any single stock or the broader equities in such a short period.

However, no matter what happens in the near term, AbbVie and Abbott Laboratories are excellent long-term picks for dividend-focused investors. Here’s why.

1. AbbVie

AbbVie’s shares dropped off a cliff in November after it announced a clinical setback for emraclidine, an investigational schizophrenia treatment it got in an $8.7 billion acquisition. Investors were worried the company spent nearly $9 billion for nothing, which is understandable.

However, AbbVie’s shares have been on a tear since that dip, and it has maintained that momentum through 2025, at least so far. Though the emraclidine setback was concerning news, AbbVie still has excellent prospects that didn’t warrant the significant drop. The company’s financial results remain strong despite losing patent exclusivity for one of the most lucrative therapies ever, Humira, about two years ago.

In 2024, AbbVie’s revenue totaled $56.3 billion, up 3.7% year over year. That’s a bit below what’s considered strong top-line growth for a pharmaceutical giant, but considering the still (relatively) fresh Humira patent cliff, it’s rather impressive that the drugmaker’s sales are moving north. AbbVie’s lineup of approved products is excellent, from its immunology medicines Skyrizi and Rinvoq to its Botox, for which we are unlikely to see biosimilars, as management argued some years ago, and newer products like migraine treatment Qulipta.

Clinical disappointments and patent cliffs will happen, but AbbVie looks ready to handle them all. The company’s pipeline has several dozen programs. AbbVie recently penned a deal with a Denmark-based company, Gubra A/S, to develop an investigational weight loss therapy, an area that has caught fire in recent years. AbbVie’s efforts in this field may or may not pay off, but the company’s solid pipeline will likely yield more blockbusters to replace its current medicines, which are still driving top-line growth.

Lastly, AbbVie is a Dividend King when we count the time it spent as a division of Abbott Laboratories — it is on a streak of 53 consecutive years of payout increases. And since splitting from Abbott, AbbVie has increased its dividends by 310%. The stock offers a forward yield of 3.1%, well above the S&P 500 index’s average of 1.3%. Whether or not AbbVie’s shares keep performing well this year, the company is a strong forever dividend stock to buy.

2. Abbott Laboratories

Abbott Laboratories is a healthcare company that operates in the medical device, nutrition, pharmaceutical, and diagnostic areas. The company is a leader in several markets where it does business. Its infant formula brand Similac is well known. During the worst of the pandemic, Abbott Laboratories marketed some of the top coronavirus diagnostic tests. Within its medical device segment, Abbott’s franchise of continuous glucose monitoring (CGM) systems, the FreeStyle Libre, is the most successful device ever in sales.

None of this happens by accident. Abbott Laboratories has fostered a culture of innovation in the many decades it has been around. It also has significant footprints and expertise navigating the challenging and highly regulated healthcare industry. Abbott Laboratories will rarely blow investors out of the water with skyrocketing revenue, but we can expect steady, reliable financial results from the company. That’s what it has offered for a long time.

ABT Revenue (Annual) data by YCharts

Abbott Laboratories should be able to profit from long-term tailwinds to continue doing the same. The company’s FreeStyle Libre, its best growth driver, still has miles of whitespace to exploit, considering that as of last year, only 1% of adults with diabetes worldwide used CGM technology. Abbott’s other medical device units, including structural heart and heart failure, offer innovative products whose demand will increase over time, given the world’s aging population.

Abbott Laboratories should deliver excellent returns in the long run while growing its payouts annually, just as it has for the past 53 straight years. Abbott’s forward yield of 1.9% might not be that impressive, but its underlying business, growth prospects, and track record all scream that it is an excellent buy-and-forget option for income seekers.

Tags: BuydefyingdipDividendIncomeLifetimemarketPassiveStockstodayheadline
Previous Post

Epson RapidReceipt RR-400W Compact Scanner Wins Prestigious GOOD DESIGN Award todayheadline

Next Post

Will Alexander-Arnold’s contract saga taint his Liverpool legacy?

Related Posts

Goodyear sees itself in prime position to capitalize on Trump auto tariffs: ‘We have a lot of opportunity in front of us’

Goodyear sees itself in prime position to capitalize on Trump auto tariffs: ‘We have a lot of opportunity in front of us’ todayheadline

May 9, 2025
3
Exclusive-Pakistan's Chinese-made jet brought down two Indian fighter aircraft, US officials say

Exclusive-Pakistan's Chinese-made jet brought down two Indian fighter aircraft, US officials say todayheadline

May 9, 2025
1
Next Post
Will Alexander-Arnold's contract saga taint his Liverpool legacy?

Will Alexander-Arnold's contract saga taint his Liverpool legacy?

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0

US oilfield giants brace for tough times as price slide rattles producers

May 9, 2025
Letter says working conditions at Regina General Hospital in question, lives at risk

Letter says working conditions at Regina General Hospital in question, lives at risk

May 9, 2025
Global digital transformation boom: How is Huawei driving cybersecurity innovation

How is Huawei driving cybersecurity innovation

May 9, 2025
FOX Super 6 INDYCAR contest: Bob Pockrass' Sonsio Grand Prix picks, predictions

FOX Super 6 INDYCAR contest: Bob Pockrass’ Sonsio Grand Prix picks, predictions

May 9, 2025

Recent News

US oilfield giants brace for tough times as price slide rattles producers

May 9, 2025
2
Letter says working conditions at Regina General Hospital in question, lives at risk

Letter says working conditions at Regina General Hospital in question, lives at risk

May 9, 2025
3
Global digital transformation boom: How is Huawei driving cybersecurity innovation

How is Huawei driving cybersecurity innovation

May 9, 2025
4
FOX Super 6 INDYCAR contest: Bob Pockrass' Sonsio Grand Prix picks, predictions

FOX Super 6 INDYCAR contest: Bob Pockrass’ Sonsio Grand Prix picks, predictions

May 9, 2025
3

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

US oilfield giants brace for tough times as price slide rattles producers

May 9, 2025
Letter says working conditions at Regina General Hospital in question, lives at risk

Letter says working conditions at Regina General Hospital in question, lives at risk

May 9, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co